Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Patterson

Showing results (111-120 of 277) with videos related to

Pageof 28
Sort By:
American Journal of Public Health|June 29, 2022
Scaling Up Evidence-Based Practices in Contraceptive Access InitiativesNikita M Malcolm, Katrin V Patterson, Ellen S Pliska, et al.
Chemmedchem|January 3, 2019
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible StructureMaria Kalyukina, Yuliana Yosaatmadja, Martin J Middleditch, et al.
Current Pharmaceutical Design|June 8, 2002
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumoursVirginia A McNally, Adam V Patterson, Kaye J Williams, et al.
Biochemical Pharmacology|October 24, 2018
Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapyJasmine V E Chan-Hyams, Janine N Copp, Jeff B Smaill, et al.
Cancer Research|October 3, 2008
Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104Shie-Chau Liu, G-One Ahn, Mitomu Kioi, et al.
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
BMC Cardiovascular Disorders|June 14, 2017
Unlocking echocardiogram measurements for heart disease research through natural language processingOlga V Patterson, Matthew S Freiberg, Melissa Skanderson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 4, 2019
Atropselective Oxidation of 2,2',3,3',4,6'-Hexachlorobiphenyl (PCB 132) to Hydroxylated Metabolites by Human Liver Microsomes and Its Implications for PCB 132 NeurotoxicityEric Uwimana, Brianna Cagle, Coby Yeung, et al.
Journal of the American Chemical Society|February 10, 2010
Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine)Sujata S Shinde, Andrej Maroz, Michael P Hay, et al.
Psychiatry Research|May 5, 1997
Effects of P50 temporal variability on sensory gating in schizophreniaY Jin, S G Potkin, J V Patterson, et al.
Pageof 28

Showing results (111-120 of 277) with videos related to

Sort By:
Pageof 28
American Journal of Public Health|June 29, 2022
Scaling Up Evidence-Based Practices in Contraceptive Access InitiativesNikita M Malcolm, Katrin V Patterson, Ellen S Pliska, et al.
Chemmedchem|January 3, 2019
TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible StructureMaria Kalyukina, Yuliana Yosaatmadja, Martin J Middleditch, et al.
Current Pharmaceutical Design|June 8, 2002
Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumoursVirginia A McNally, Adam V Patterson, Kaye J Williams, et al.
Biochemical Pharmacology|October 24, 2018
Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapyJasmine V E Chan-Hyams, Janine N Copp, Jeff B Smaill, et al.
Cancer Research|October 3, 2008
Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104Shie-Chau Liu, G-One Ahn, Mitomu Kioi, et al.
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
BMC Cardiovascular Disorders|June 14, 2017
Unlocking echocardiogram measurements for heart disease research through natural language processingOlga V Patterson, Matthew S Freiberg, Melissa Skanderson, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 4, 2019
Atropselective Oxidation of 2,2',3,3',4,6'-Hexachlorobiphenyl (PCB 132) to Hydroxylated Metabolites by Human Liver Microsomes and Its Implications for PCB 132 NeurotoxicityEric Uwimana, Brianna Cagle, Coby Yeung, et al.
Journal of the American Chemical Society|February 10, 2010
Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine)Sujata S Shinde, Andrej Maroz, Michael P Hay, et al.
Psychiatry Research|May 5, 1997
Effects of P50 temporal variability on sensory gating in schizophreniaY Jin, S G Potkin, J V Patterson, et al.
Pageof 28